Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 92 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Bladder Carcinoma Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Non-muscle-invasive Bladder Cancer
Interventions
PLZ4-coated paclitaxel-loaded micelles (PPM)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
Everolimus and Intravesical Gemcitabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced May 21, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions
Tovorafenib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer of the Bile Duct
Interventions
Regorafenib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Tampa, Florida • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced May 21, 2026, 10:10 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Carcinoma in Situ of Bladder
Interventions
Not listed
Lead sponsor
Endo Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2014 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma
Interventions
OGX-427, Docetaxel
Drug
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
35
States / cities
Birmingham, Alabama • Duarte, California • Lancaster, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
valrubicin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
10
States / cities
Tampa, Florida • Urbana, Illinois • East Orange, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 4 Interventional
View directory record Official record
Conditions
Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions
Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced May 21, 2026, 10:10 PM EDT
Withdrawn Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I
Interventions
Pharmacokinetic Study, Recombinant EphB4-HSA Fusion Protein
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
TTX-030, Pembrolizumab, Gemcitabine, nab paclitaxel
Drug
Lead sponsor
Trishula Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Orange, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced May 21, 2026, 10:10 PM EDT
Enrolling by invitation Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
keyhole limpet hemocyanin, doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Intracel
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer, Salivary Gland Cancer, Salivary Gland Tumor, Salivary Gland Carcinoma, Salivary Gland Neoplasms, Lung Cancer, Colo-rectal Cancer, Rare Diseases, Solid Tumor, Recurrent Gastric Cancer, Recurrent Colon Cancer, Recurrent Breast Cancer, Head and Neck Cancer, Head and Neck Carcinoma, Bladder Cancer, Cervical Cancer, Liver Cancer, Bile Duct Cancer, Urologic Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Prostate Cancer, Rectal Cancer, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Cancer, Rectal Cancer Stage II, Rectal Cancer Stage I, Rectal Cancer Stage III, Skin Cancer, Mouth Cancer, Lip Cancer Stage I, Tongue Cancer, Breast Neoplasm Malignant Primary, Larynx Cancer, Tonsil Cancer, Palate Cancer, Mucoepidermoid Carcinoma, Primary Peritoneal Carcinoma, Mucinous Adenocarcinoma Gastric, Mucinous Breast Cancer Recurrent, Cholangiocarcinoma
Interventions
A166
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Sarasota, Florida • Boston, Massachusetts • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced May 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Guadecitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
PLZ4-coated paclitaxel loaded micelles (PPM)
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Bladder Cancer, Kidney Cancer, Lung Cancer
Interventions
tucotuzumab celmoleukin
Biological
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:10 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Cancer, Bladder Cancer
Interventions
Lapatinib and Paclitaxel
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced May 21, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma in Situ of Bladder, Bladder Cancer
Interventions
Durvalumab, Cystoscopy with Biopsy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Miami Beach, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Renal Pelvis and Ureter Cancer AJCC v7
Interventions
Best Practice, Biospecimen Collection, Central Venous Cannula Insertion, Computed Tomography, Enfortumab Vedotin, Magnetic Resonance Imaging, Pembrolizumab, Plasmapheresis, Positron Emission Tomography, Questionnaire Administration, Antibody-Drug Conjugate Therapy
Other · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 10:10 PM EDT